© Provided by Benzinga Boston Scientific Corporation (NYSE: BSX) announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres (TheraSphere treatment) met both primary endpoints. The results of a long-term study showed that adding TheraSpheres to a standard chemotherapy regimen could extend survival for patients with colorectal cancer that has spread to the liver. Each of the beads contains a small but mighty dose of Y-90, a radioactive isotope of yttrium with a half-life of fewer than three days. The beads are planted directly in a tumor by a catheter, helping minimize the dose and damage to nearby healthy tissues. In the study, TheraSpheres were used in tandem with chemotherapy as a second-line treatment for liver-dominant colorectal cancer patients who saw their disease worsen either during or after their chemo. TheraSpheres were found to be 31% less likely than the control group to show disease progression or death due to any cause and just over 40% less likely to experience hepatic disease progression or death. Earlier this year, TheraSpheres was approved by the FDA for hepatocellular carcinoma, the most common type of primary liver cancer. Related content: Benzinga’s Full FDA Calendar. Price Action: BSX stock closed lower by 1.63% at $43.65 on Monday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Internet Explorer Channel Network